Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Prof Cameron and Best's group in collaboration with Dr Ghevaert have published a paper in Biomaterials showing platelet production from in vitro derived megakaryocytes. Platelet production has always been the bottle neck in the venture to produce platelets for human use in the laboratory. This paper illustrates a very important step to make this a reality and illustrates a brilliant collaboration across disciplines and groups who are part of the BHF Oxbridge Centre of Regenerative Medicine.

The researchers cultured megakaryocytes from induced stem cells on a specialised growth support within a flow chamber that mimics features of the bone marrow. The system is able to produce an out flow of platelets that can take part in clotting. It is hoped that the system will aid in mass production of in vitro platelets and modified platelets as responsive drug delivery devices. The full paper can be found here.

See also

Shepherd et al, Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity. Biomaterials. 2018.

Moreau et al, Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Comms. 2016.

Similar stories

High blood sugar levels ‘reprogramme’ stem cells

Findings explain higher risk of heart attack in people with diabetes, even after treatment .

Critical six-week window to ‘reset’ blood pressure after giving birth

Home blood pressure monitors could help mothers significantly lower high blood pressure after pregnancy

Iron deficiency anaemia in early pregnancy increases risk of heart defects, suggests new research

In animal models, iron deficient mothers have a greatly increased risk of having offspring with congenital heart disease (CHD). The risk of CHD can be greatly reduced if the mother is given iron supplements very early in pregnancy. Additionally, embryos from a mouse model of Down Syndrome were particularly vulnerable to the effects of maternal iron deficiency, leading to a higher risk of developing severe heart defects.

Nicola Smart to deliver John French Lecture

The British Atherosclerosis Society's John French Memorial Lecture is named in honour of the Oxford-based pathologist, Dr John French, who made seminal observations and contributions to the field of cardiovascular pathology.